Pierre Cassigneul is the president and chief executive officer for XDx. Mr. Cassigneul has more than 20 years of senior management experience in the healthcare and medical device industries, both in Europe and the United States, including the global launch of several successful high-tech products. He joined XDx from the consulting firm, Stone Bridge Management LLC, where he was an operating partner. Formerly, as the vice president of diabetes management at Becton Dickinson & Co, he oversaw completion of the product, clinical trials and regulatory submissions. Mr. Cassigneul has held top management positions at Bayer in the diabetes self-testing business unit, where he developed and launched a new patient-monitoring system; Ortho Diagnostic Systems (J&J) in the AIDS and hepatitis business unit, where he launched a complete line of blood screening products; and Abbott Laboratories in the diagnostic division, where he launched the first HIV test for screening the European blood supply. Mr. Cassigneul holds a management degree from the Ecole Superieure de Commerce de Reims, France.
XDx, Inc. is a molecular diagnostics company focused on the discovery, development and commercialization of noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed a proprietary new method for noninvasively monitoring immune system activity by measuring gene expression in a patient’s peripheral blood. This work is the basis for AlloMap® molecular expression testing, which provides transplant physicians with a new tool to aid in the identification of the probability of acute cellular rejection for postcardiac transplant patient management. Join us to learn about the company, its product, and future plans.
